Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Depression
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period. After recruitment written informed consent form will be signed and the baseline evaluation will be done then the treatment period follows. The subjects will be randomly assigned to a control group (escitalopram plus normal saline(NA)) and an ATP group (escitalopram plus adenosine disodium triphosphate(ATP)) in a 1:1 ratio for treatment, with a total number of 120 recruited patients. Assessment will be carried out as an analysis of changes in Hamilton Depression Scale(HAMD-24), cognitive function test, brain functional network, inflammatory markers, and other indicators in the first, second, and fourth week of intervention which will evaluate the effectiveness of ATP in improving moderate to severe depression preliminarily.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: ATP Group — Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
  • Drug: Placebo Group — Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.

Primary Outcomes

  • HAMD-24 (Baseline, two weeks, and four weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-04
Completion: 2026-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanfang Hospital, Southern Medical University
Contact Information
Study Contact:
Bin Zhang, PhD
86-020-62786731
zhang73bin@hotmail.com
Qianqian Xin, MMed
86-020-62786731
Qianqian Xin
17664175246
xinqianqian0126@163.com
Nanfang Hospital, Southern Medical University
Interventions
  • Drug: ATP Group — Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
  • Drug: Placebo Group — Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
Study Locations (1 sites)
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515 China
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic and statistical manual of mental disorders-5 diagnostic criteria for moderate to severe depression. * HAMD-24 scores ≥ 20. * 18-65 female or male. * Participants who have not used any psychotropic medications within one month prior to study and never had a treatment with escitalopram. * Individuals without contraindications to selective serotonin reuptake inhibitor. * Individuals without contraindications to ATP. * Written informed consent. Exclusion Criteria: * Participants with various major mental disorders other than depression (bipolar disorder, any psychotic disorder, Personality Disorders, alcohol use disorder, substance use disorder, and disorders due to medical or organic cause) assessed using Chinese version of the Mini International Neuropsychiatric Interview (MINI). * Individuals with neurological disorders such as dementia. * Individuals with a high risk of suicide. * Pregnant and lactating women. * Contraindications to MRI. * Physician evaluation was not suitable for participants in this study.
Conditions Anxiety Disorders, Depression
Phase NA
Enrollment 100
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This randomized clinical trial aims to evaluate the effects of mentalization-based group psychotherapy in patients diagnosed with anxiety and/or depression disorders. In total 100 users of mental health communitary services will be recruited for this study. Participants will be randomized in two parallel groups: to receive usual acceptance and commitment therapy group intervention (control group) or to receive brief mentalization-based group psychotherapy (intervention group). Participants in the trial will be assessed at baseline and at 3 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Brief mentalization-based group psychotherapy — The intervention is an adaptation for anxiety and depression profiles of the introductory group program to Mentalization-Based Treatment for personality disorders. Sessions program: * Session 1: Building epistemic trust. * Session 2: Introduction to mentalization. * Session 3: Mentalization problems. * Session 4: Emotions. * Session 5: Mentalizing emotions. * Session 6: Attachment relationships. * Session 7: Attachment and mentalization. * Session 8: Interpersonal relationships. Mentalizing relationships in the group. * Session 9: Anxiety, attachment and mentalization. * Session 10: Depression, attachment and mentalization. * Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing * Session 12: Final balance and closing.
  • Behavioral: Acceptance and Commitment Therapy group intervention — The intervention includes 12 sessions based on Acceptance and Commitment Therapy. Sessions program: * Session 1: Presentation. * Session 2: Cognitive defusion * Session 3: Uncontrollability of thought, emotions and behavior. * Session 4: Creative Hopelessness. * Session 5: Mindfulness and acceptance. * Session 6: Values. * Session 7: Values and action. * Session 8: Vital goals. * Session 9: Goal achievement plan. * Session 10: Implementation. * Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing * Session 12: Final balance and closing.

Primary Outcomes

  • Change from baseline anxiety symptoms at 3 months. (At baseline then at 3 months.)
  • Change from baseline depressive symptoms at 3 months. (At baseline then at 3 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-28
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Contact Information
Study Contact:
Maria Traverso Rodriguez
+34 660512210
mariatraverso8@gmail.com
Maria Traverso
+34 660512210
mariatraverso8@gmail.com
Instituto de Investigacion Biomedica de Malaga - IBIMA
Maria Traverso Rodriguez
Instituto de Investigacion Biomedica de Malaga - IBIMA
Interventions
  • Behavioral: Brief mentalization-based group psychotherapy — The intervention is an adaptation for anxiety and depression profiles of the introductory group program to Mentalization-Based Treatment for personality disorders. Sessions program: * Session 1: Building epistemic trust. * Session 2: Introduction to mentalization. * Session 3: Mentalization problems. * Session 4: Emotions. * Session 5: Mentalizing emotions. * Session 6: Attachment relationships. * Session 7: Attachment and mentalization. * Session 8: Interpersonal relationships. Mentalizing relationships in the group. * Session 9: Anxiety, attachment and mentalization. * Session 10: Depression, attachment and mentalization. * Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing * Session 12: Final balance and closing.
  • Behavioral: Acceptance and Commitment Therapy group intervention — The intervention includes 12 sessions based on Acceptance and Commitment Therapy. Sessions program: * Session 1: Presentation. * Session 2: Cognitive defusion * Session 3: Uncontrollability of thought, emotions and behavior. * Session 4: Creative Hopelessness. * Session 5: Mindfulness and acceptance. * Session 6: Values. * Session 7: Values and action. * Session 8: Vital goals. * Session 9: Goal achievement plan. * Session 10: Implementation. * Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing * Session 12: Final balance and closing.
Study Locations (1 sites)
Instituto de Investigacion Biomedica de Malaga - IBIMA, Málaga, Malaga 29009 Spain
Eligibility Criteria
Inclusion Criteria: * Participants are 18 years or older. * Participants have a diagnosis of ICD-10 F32, F33, F34, F41.1, F41.2, F43 or F43.2. * Participants have minimal relational skills to participate in group therapy. * Participants agree to be part of the study by giving signed written consent. Exclusion Criteria: * Participants have a diagnosis of ICD-10 F10-19, F20-29, F31, F42, F43.1, F60. * Participants with cognitive deficits assessed during the initial interview or diagnosis of ICD-10 F70-79. * Participants with planning or structured suicidal ideation. * Participants with difficulties in relational skills evaluated during the initial interview.
Conditions Heart Failure, Mental Health, Stress, An...
Phase NA
Enrollment 7300
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Heart Failure and Mental Health Intervention (FRAME) — Foundation, Recognition, Awareness, Management and Engagement (FRAME) is a multi-component, co-designed web tool created in collaboration with patient partners, caregivers, healthcare providers, and Archipel and Great River Ontario Health Teams. It is designed to improve recognition, awareness, management and support for mental health in patients with heart failure. There are three different versions: one for healthcare providers, one for caregivers and one for patients. The intervention includes educational material about heart failure and mental health, conversational support to help facilitate discussions about mental health, self-management activity maps (e.g., tips about nutrition and exercise), asset maps (i.e., displaying available resources), and the provider-facing discussion tool to help initiate conversations about mental health and guide referrals or supports. FRAME was developed through a co-design process informed by the lived experiences of community partners.

Primary Outcomes

  • Frequency of Mental Health Conversations (Baseline, and up to 6 months following intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-26
Completion: 2026-11-30
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 7300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bruyère Health Research Institute.
Collaborators: Canadian Institutes of Health Research (CIHR)
Contact Information
Study Contact:
Krystal Kehoe MacLeod, PhD
613-862-4314
kmacleod@bruyere.org
Krystal Kehoe MacLeod Principal Investigator
613-862-4314
kmacleod@bruyere.org
Bruyère Health Research Institute
Krystal Kehoe MacLeod Principal Investigator
Bruyère Health Research Institute
Interventions
  • Other: Heart Failure and Mental Health Intervention (FRAME) — Foundation, Recognition, Awareness, Management and Engagement (FRAME) is a multi-component, co-designed web tool created in collaboration with patient partners, caregivers, healthcare providers, and Archipel and Great River Ontario Health Teams. It is designed to improve recognition, awareness, management and support for mental health in patients with heart failure. There are three different versions: one for healthcare providers, one for caregivers and one for patients. The intervention includes educational material about heart failure and mental health, conversational support to help facilitate discussions about mental health, self-management activity maps (e.g., tips about nutrition and exercise), asset maps (i.e., displaying available resources), and the provider-facing discussion tool to help initiate conversations about mental health and guide referrals or supports. FRAME was developed through a co-design process informed by the lived experiences of community partners.
Study Locations (9 sites)
Seaway Valley Community Health Centre (Cardiac Rehab Program), Cornwall, Ontario Canada
Centre de Santé Communautaire de l'Estrie, Limoges, Ontario Canada
Orleans Cardiopulmonary Clinic, Orléans, Ontario Canada
Bruyère Health Research Institute, Ottawa, Ontario K1N 5C8 Canada
Byward Family Health Team, Ottawa, Ontario Canada
Montfort Hospital, and associated Aline-Chrétien Rehabilitation Clinic, Ottawa, Ontario Canada
Ste-Anne Medical Clinic, Ottawa, Ontario Canada
University of Ottawa Heart Institute, Ottawa, Ontario Canada
Winchester Memorial Hospital, Winchester, Ontario Canada
Eligibility Criteria
Inclusion Criteria: For Patients (Surveys and Optional Interviews): * Patients at risk of heart failure (e.g., irregular heartbeat, coronary artery disease, a past heart attack, high blood pressure that is being treated, cardiomyopathy), or with a self-reported/documented diagnosis of heart failure OR on the following list of medications : * Angiotensin receptor-neprilysin inhibitors (ARNI), called sacubitril-valsartan * Angiotensin converting enzyme inhibitors (ACEi), called "prils" * Angiotensin-receptor blockers (ARBs), called "sartans" * Beta-blockers, called "lols" * Mineralocorticoid receptor antagonists (MRAs) * Sodium-glucose co-transporter-2 (SGLT2) inhibitors, called "flozins" * Receiving care at one of the participating pilot test sites or if they found their way to the tool website * Willing and able to provide informed consent and name, email address and phone number for follow-up contact (for survey and interview) Caregivers (Optional interviews): * Caregivers who support adult(s) with heart failure. Exclusion Criteria: * Inability to provide informed consent (e.g., due to cognitive impairment or language barriers without translated support) * Participants who do not have access to the internet will not be able to use the web-tool. For Healthcare Providers * Providers that are not involved in the care of heart failure patients
Conditions HIV, Depression, Depression, Postpartum
Phase NA
Enrollment 400
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of the proposed study is to evaluate the effectiveness of the Enhanced Friendship Bench intervention to improve perinatal depression, HIV care engagement, and infant health outcomes among pregnant women with HIV and depression in Malawi.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Enhanced Friendship Bench — Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.
  • Behavioral: Enhanced usual care — Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.

Primary Outcomes

  • Change in Depressive Symptoms (6 months post partum)
  • HIV Care Retention (6 months post partum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-26
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Brian Pence, PhD, MPH (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Brian Pence, PhD, MPH
1-919-966-7446
bpence@unc.edu
Angela Bengtson, PhD, MA
angelabengtson@emory.edu
Steve Mphonda
265-1755056
smphonda@unclilongwe.org
Area 18 Health Center
Interventions
  • Behavioral: Enhanced Friendship Bench — Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.
  • Behavioral: Enhanced usual care — Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
Study Locations (5 sites)
Area 18 Health Center, Lilongwe, Malawi
Area 25 Health Center, Lilongwe, Malawi
Bwaila Hospital, Lilongwe, Malawi
Kawale Health Center, Lilongwe, Malawi
Likuni Mission Hosptial, Lilongwe, Malawi
Eligibility Criteria
Inclusion Criteria: * Presenting for antenatal care at one of our 5 recruitment sites * ≥ 18 years of age * ≤ 34 weeks gestation * HIV-positive, based on medical records * Initiating, re-initiating, or on established ART during index pregnancy * Elevated depressive symptoms as indicated by a EPDS score ≥10. The EPDS is widely used to assess perinatal mood disorders that has been validated in perinatal populations in Malawi with this cut point to identify probable perinatal depression Exclusion Criteria: * Suicidal ideation evaluated as acute risk. * Other health concerns requiring emergent response.
Conditions Suicidal Ideation, Suicide Attempt, Anxi...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pilot study is to test the effectiveness of a novel intervention for teenagers (ages 15-18) with mental health conditions who have been released from an acute care psychiatric facility. The intervention aims to reduce suicidality, depression, anxiety, re-hospitalization, and to improve mental health recovery by using an online recovery education and support program. The current standard of care (SOC) for these patients at discharge includes a discharge plan with a list of their medication(s), anticipated outpatient appointment(s), and corresponding information on when and where to find community resources. The intervention being tested involves the implementation of an online recovery education and support (RES) program, involving one-on-one and small group meetings led by trained teen peers (TPs) and peer support specialists (PSS). Participants will be assigned to either Cohort A or B for 8 weeks. Cohort A will be the intervention group with online access to an RES, TP, and PSS. * Week 1-4: One-on-one meetings with PSS and TP for education and support. Assessments will be completed at week 2 and 4. * Week 5 and 7: one-one meetings with PSS and TP for education and support. * Week 6 and 8: small group meetings with PSS, TP, and other participants. Assessments will be completed during Weeks 6 and 8. Cohort B will be the SOC group with no PSS, TP, or RES. * Weeks 1-4: Weekly check in phone calls with a member of the research team. Assessments will be completed at Weeks 2 and 4. * Weeks 5-8: Check in phone calls with a member of the research team every other week. Assessments will be completed at weeks 6 and8. Data collected from participant assessments, adherence to medication, and re-admittance to a psychiatric facility will be used to compare the intervention to the SOC.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Peer Support Services Recovery — A program of mental health recovery through one-on-one and small group meetings with a PSS and TP using RES for individuals recently discharged from an acute care psychiatric facility.

Primary Outcomes

  • Change in Suicidal Ideation as measured by C-SSRS at 2 weeks from baseline (Baseline, 2 weeks)
  • Change in Suicidal Ideation as measured by C-SSRS at 4 weeks from baseline (Baseline, 4 weeks)
  • Change in Suicidal Ideation as measured by C-SSRS at 6 weeks from baseline (Baseline, 6 weeks)
  • Change in Suicidal Ideation as measured by C-SSRS at 8 weeks from baseline (Baseline, 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-05
Completion: 2026-11
Eligibility
Age: 15 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Principal Investigators:
  • Joseph Guillory, M.D. (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Cameron M Pham
214-648-4885
cameron.pham@utsouthwestern.edu
Interventions
  • Behavioral: Peer Support Services Recovery — A program of mental health recovery through one-on-one and small group meetings with a PSS and TP using RES for individuals recently discharged from an acute care psychiatric facility.
Study Locations (1 sites)
The University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: * Chief complaint of suicidal ideation, suicide attempt, depression, and/or anxiety * recently discharged from inpatient care or from emergency department * men and women ages 15-18 years old Exclusion Criteria: \- primary diagnosis of: substance use disorder, schizophrenia spectrum, intellectual development disorder, autism spectrum disorder (level II or III)
Conditions Loneliness, Social Support, Depressive S...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates a Just-In-Time Adaptive Intervention (JITAI) aiming to foster social support processes for adults with elevated depressive symptoms awaiting outpatient psychotherapy. Utilizing a daily-level micro-randomized trial (MRT) design conducted over 21 days, participants are assessed six times daily. Participants are randomized across four conditions: (1) vulnerability-triggered, (2) vulnerability and receptivity-triggered, (3) support-need-triggered, and (4) a no-intervention control. The primary objective of this study is to evaluate the effectiveness of the JITAI in reducing daily depressive symptoms and increasing received social support (primary outcomes), as well as reducing daily loneliness and enhancing perceived social support (secondary outcomes). Furthermore, the study aims to compare the relative efficacy of three distinct triggering strategies to identify the most effective timing for intervention delivery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Social Support Just-in-Time Adaptive Intervention — The intervention is a smartphone-based system designed to encourage the activation of social support networks during critical moments. Triggers are based on real-time Ecological Momentary Assessment (EMA) data. When a condition is met, the app prompts participants to identify a specific type of support needed and a person from their social network to contact. It then provides one of three evidence-based recommendations to facilitate effective support-seeking behavior (direct communication, solution-focused discussion, and reframing the situation). If no social contact is available, the app suggests alternative self-help activities. Detailed information can be found on the OSF project page: https://osf.io/4e8gz

Primary Outcomes

  • Depressive Symptoms (Measured in the evening of study days 1-21)
  • Received Social Support (Measured in the evening of study days 1-21)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-22
Completion: 2026-12
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Zurich
Contact Information
Study Contact:
Timon Elmer, PhD
+41 44 635 72 65
timon.elmer@uzh.ch
University of Zurich
Interventions
  • Behavioral: Social Support Just-in-Time Adaptive Intervention — The intervention is a smartphone-based system designed to encourage the activation of social support networks during critical moments. Triggers are based on real-time Ecological Momentary Assessment (EMA) data. When a condition is met, the app prompts participants to identify a specific type of support needed and a person from their social network to contact. It then provides one of three evidence-based recommendations to facilitate effective support-seeking behavior (direct communication, solution-focused discussion, and reframing the situation). If no social contact is available, the app suggests alternative self-help activities. Detailed information can be found on the OSF project page: https://osf.io/4e8gz
Study Locations (1 sites)
University of Zurich, Zurich, Canton of Zurich 8050 Switzerland
Eligibility Criteria
Inclusion Criteria: * indicating to seek outpatient psychotherapy * elevated levels of self-reported depressive symptoms (Beck Depression Inventory-II (BDI) score \> 13 (out of 63); Kühner et al., 2007) * owning a smartphone * signing the informed consent form Exclusion Criteria: * first session for outpatient psychotherapy is scheduled within four weeks * suicidal ideation (values \> 2 in BDI item 9) * presence of manic symptoms (Mood Disorder Questionnaire (MDQ) score \> 7), - shift work * age below 18 or above 70
Conditions Rheumatoid Arthritis, Sjogren's Syndrome...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological conditions, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), psoriatic arthritis (PsA), anxiety disorders, depressive disorders and moderate depression. Additionally, investigators will assess the program's effectiveness, as well as the challenges and facilitators involved in using an online wellness program to reduce fatigue and enhance the quality of life in patients suffering from these conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Creating Health Online Course — Immediate access to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
  • Behavioral: Delayed access to Creating Health Online Course — Delayed access (12-week delay) to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care

Primary Outcomes

  • Modified Fatigue Impact Scale (MFIS) (Day 0 to Month 3)
  • Modified Fatigue Impact Scale (MFIS) (Day 0 to Month 6)
  • Fatigue Severity Scale (FFS) (Day 0 to Month 3)
  • Fatigue Severity Scale (FFS) (Day 0 to Month 6)
  • Short form 36 (SF 36) (Day 0 to Month 3)
  • Short form 36 (SF 36) (Day 0 to Month 6)
  • Rapid 3 (Day 0 to Month 3)
  • Rapid 3 (Day 0 to Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-01
Completion: 2027-12-31
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Terry L. Wahls
Principal Investigators:
  • Terry L Wahls, MD, Other (PRINCIPAL_INVESTIGATOR) - University of Iowa
Contact Information
Study Contact:
Study Coordinator
319 384 5002
ch-studies@uiowa.edu
Mary Ehlinger, BS
319 384 5002
AIM-Studies@uiowa.edu
Mary Ehlinger, BS
319-384-5002
CH-studies@uiowa.edu
Univeristy of Iowa
Interventions
  • Behavioral: Creating Health Online Course — Immediate access to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
  • Behavioral: Delayed access to Creating Health Online Course — Delayed access (12-week delay) to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
Study Locations (1 sites)
Univeristy of Iowa, Iowa City, Iowa 52246 United States
Eligibility Criteria
Inclusion criteria: 1. A diagnosis of one of the following: Rheumatoid Arthritis (RA), Sjogren's Syndrome, Systemic lupus erythematosus (SLE), Mixed connective tissue disease (MCTD), or Psoriatic Arthritis (PsA), as documented by their treating specialist or primary care provider, as reported by the participant. 2. Must be age 18 and older, at time of consent. 3. Must be fluent in both speaking and reading English. \*Study participant must be able to read and comprehend informed consent document and speak with study staff about study document content. Study staff will use discretion in determining whether the study participant can clearly communicate with staff and comprehend the study material during the consent call or prior to the call. 4. Must have access to high-speed internet with devices capable of audio/video streaming. 5. Must be willing to participate in an online health course designed to improve dietary intake and self-care routines to help improve cellular function and health, and complete online surveys over the course of a 6-month period. 6. Individuals must pass the Short Portable Mental Status Questionnaire with scores for normal mental functioning (up to 2 errors). Cognitive impairment as measured by the SPMS Questionnaire could interfere with the completion of the online course. SCORING\* 0-2 errors: normal mental functioning 3-4 errors: mild cognitive impairment 5-7 errors: moderate cognitive impairment 8-10 errors: severe cognitive impairment \*Allow one more error for a subject with only a grade school education. Allow one less error for a subject with education beyond high school. Source: Pfeiffer, E. (1975). A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Journal of American Geriatrics Society. 23, 433-41. Exclusion criteria: 1. Inability to provide informed consent, including participation in a consent call conducted via Zoom with the study team during business hours (8:00 a.m. to 5:00 p.m. Central Time (Chicago)). 2. Participation in another research study investigating an intervention (treatments, medications, diet, or exercise). Participation in observation-only studies are not excluded. 3. Currently following a modified Paleolithic, low-fat nutrient-dense vegetarian, or Mediterranean diet with 75% OR greater reported compliance. 4. Any diagnosis or condition that is contraindicated from starting a gentle exercise program (ex. poorly controlled diseases of the heart, kidney, or liver in the prior 12 months, or severe psychiatric disease, e.g., schizophrenia, making adherence to study procedures difficult.
Conditions Glaucoma, Biofeedback Training
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled clinical trial evaluates the efficacy of visual biofeedback training on visual function and quality of life in individuals with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to irreversible vision loss, including impaired fixation stability, reduced retinal sensitivity, and decreased functional vision. Biofeedback training is a visual rehabilitation technique designed to help patients improve fixation stability and optimize use of remaining visual function by training eye movements toward retinal areas with better sensitivity. Seventy participants with glaucoma will be randomized to either a biofeedback training intervention group or a control group. Visual function outcomes, including fixation stability, retinal sensitivity, visual acuity, reading speed, contrast sensitivity, and quality of life, will be assessed at baseline and follow-up visits. This study aims to determine whether biofeedback training can improve visual function and quality of life in patients with glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Biofeedback Training — Visual Biofeedback Training

Primary Outcomes

  • Quality of Life Questionnaire (Baseline, 9 weeks, 6 months, 1 year and 2 years.)
  • Visual acuity (Baseline and follow-up visits at 9 weeks, 6 months, 1 year, and 2 years post-intervention)
  • Fixation Stability (Baseline, 9 weeks, 6 months, 1 year and 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-10
Completion: 2028-06
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Contact Information
Study Contact:
Monica Daibert-Nido, MD
416-603-5470
monica.nido@uhn.ca
University Health Network/ Toronto Western Hospital
Interventions
  • Other: Biofeedback Training — Visual Biofeedback Training
Study Locations (1 sites)
University Health Network/ Toronto Western Hospital, Toronto, Ontario M5T 2S8 Canada
Eligibility Criteria
Inclusion Criteria: * 18-95 years old. * Glaucoma cases with adequate intraocular pressure control. * Presence of paracentral scotomata within two degrees of fixation. * Ability to follow instructions for biofeedback training. Exclusion Criteria: * Prior or current low vision rehabilitation treatment. * Ocular diseases or severe clinical conditions unrelated to glaucoma * Media opacities that prevent reliable microperimetry testing in both eyes. * Inability to perform study assessments or follow instructions for biofeedback training.
Conditions Glaucoma, Open-Angle
Phase PHASE4
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Travoprost Intraocular Implant — anchored intracameral implant containing travoprost
  • Device: iStent infinite — Successful iStent infinite surgery
  • Other: Sham procedure — Sham procedure (to mimic placement of an iStent infinite)

Primary Outcomes

  • change from baseline in mean diurnal intraocular pressure (IOP) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-09-14
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Glaukos Corporation
Principal Investigators:
  • Study Director (STUDY_DIRECTOR) - Glaukos Corporation
Contact Information
Study Contact:
Study Director
949-739-8749
idoseclinical@glaukos.com
Study Manager
949-739-8749
idoseclinical@glaukos.com
Study Director
949-739-8749
idoseclinical@Glaukos.com
Glaukos Clinical Study Site
Interventions
  • Drug: Travoprost Intraocular Implant — anchored intracameral implant containing travoprost
  • Device: iStent infinite — Successful iStent infinite surgery
  • Other: Sham procedure — Sham procedure (to mimic placement of an iStent infinite)
Study Locations (1 sites)
Glaukos Clinical Study Site, Oklahoma City, Oklahoma 73112 United States
Eligibility Criteria
Inclusion Criteria: * diagnosis of open-angle glaucoma or ocular hypertension * qualifying IOP in the study eye Exclusion Criteria: * unmedicated (washed out) IOP of \>36 mmHg in the study eye * hypersensitivity to travoprost or any other components of the travoprost intraocular implant * vertical cup/disc ratio \> 0.8 in the study eye * best spectacle corrected visual acuity of worse than 20/80 in either eye * any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Conditions Pulmonary Hypertension
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary hypertension (PH) is a serious condition that puts strain on the heart and lungs and often leads to frequent hospital stays and shortened life expectancy. The most common cause is heart disease affecting the left side of the heart. A particularly high-risk form, called combined pre- and post-capillary pulmonary hypertension (CPH), occurs in about one in four people with heart failure. There are currently no approved treatments for CPH, and many patients develop right-sided heart failure and die earlier than expected. This study is based on a new approach that uses advanced computer methods to analyze a patient's unique biology and identify potential drug targets. Using this method, we identified nicotinamide riboside (NR) as a promising option for people with CPH. NR is a form of vitamin B3 that helps the body make NAD⁺, a substance essential for how cells produce energy and stay healthy. NAD⁺ plays an important role in how heart and blood vessel cells function. Previous research in animals suggests NR may help improve blood vessel changes in the lungs and support heart function. NR has also shown potential benefits in human studies related to cell energy, mitochondrial health, and reducing oxidative stress. In this study, NR is used only as a dietary supplement that supports normal body processes, not as a proven treatment. The investigators will conduct a small, carefully controlled study in which participants receive NR and a placebo at different times. The goal is to understand how NR affects biological and biochemical markers in the body, not to test whether it improves symptoms or outcomes. Any clinical measurements are included only to help interpret the biological effects.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Nicotinamide Riboside (NR) — Participants will be randomized to receive either 1000mg NR Daily or a placebo for 6 weeks, followed by a 3-week washout period. After this, they will receive the alternate treatment for an additional 6 weeks.
  • Drug: Placebo — Participants will be randomized to receive either NR or a placebo for 6 weeks, followed by a 3-week washout period. After this, they will receive the alternate treatment for an additional 6 weeks.

Primary Outcomes

  • Biochemical: Change in NADH:Ubiquinone Oxidoreductase Subunit B7 (Baseline, Week 6, Week 9, Week 15)
  • Exploratory physiological measure: Change in 6-minute walk distance (Baseline, Week 6, Week 9, Week 15)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-09
Completion: 2027-07-30
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Evan L Brittain, MD (PRINCIPAL_INVESTIGATOR) - VUMC
Contact Information
Study Contact:
Thomas E Strayer, PhD
615-936-0156
thomas.e.strayer@vumc.org
Thomas E Strayer, PhD
615-936-0156
thomas.e.strayer@vumc.org
Vanderbilt University Medical Center
Evan L Brittain, MD
Vanderbilt University Medical Center
Interventions
  • Dietary Supplement: Nicotinamide Riboside (NR) — Participants will be randomized to receive either 1000mg NR Daily or a placebo for 6 weeks, followed by a 3-week washout period. After this, they will receive the alternate treatment for an additional 6 weeks.
  • Drug: Placebo — Participants will be randomized to receive either NR or a placebo for 6 weeks, followed by a 3-week washout period. After this, they will receive the alternate treatment for an additional 6 weeks.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37203 United States
Eligibility Criteria
Inclusion Criteria: * Aged \>/= 18 to 85 years of age * Diagnosis of Combined pre-/post-capillary PH (CPH) defined as mean pulmonary artery pressure \>20mmHg, pulmonary capillary wedge pressure \>15mmHg, and pulmonary vascular resistance ³3 Wood units * NYHA Class I - III * A qualifying Baseline RHC performed within 2 years of consent Clinical echocardiogram within the prior year with LVEF\>/= 45% * Stable PH-specific and/or HF medication regimen and ≤1 diuretic adjustment within the three months prior to enrollment. * Ambulatory - able to perform the walk test Exclusion Criteria: * Pulmonary hypertension due to congenital heart disease, connective tissue disease, or heritable pulmonary arterial hypertension * Prohibited from regular activity due to wheelchair bound status, bed-bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other conditions that limit activity * Pregnancy * Drug and toxin-associated PAH patients with active drug use * Prior or active diagnosis of cirrhosis * Active Malignancy * Patients with evidence of moderate to severe hepatic impairment, defined as Child-Pugh Class B or C, or with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the upper limit of normal (ULN), should be excluded * eGFR by MDRD \<30mL/mi * FEV1\< 60% predicted with more than mild abnormalities on lung imaging Current enrollment in or completion of any other investigational product study within 30 days of Screening. * Hospitalization for any indication within 30 days of Day 1. * History of severe allergic or anaphylactic reaction or hypersensitivity to NR * No known mutation in NDUFB7
Conditions Postpartum, Hypertension, Hypertensive D...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Postpartum remote blood pressure monitoring programs for patients with hypertensive disorders of pregnancy (HDP) are becoming part of standard postpartum management. Existing programs range in duration from 2 to 6 weeks but there has not been any evaluation as to what program duration is optimal. The primary objective of this study is to evaluate the impact of program duration on clinical outcomes for patients participating in a single institution's postpartum remote blood pressure monitoring program for patients with HDP.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 2-Week Home Monitoring — Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.
  • Diagnostic Test: 6-Week Home Monitoring — HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.

Primary Outcomes

  • Diastolic Blood Pressure (Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-07
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Principal Investigators:
  • Bethany Sabol, MD MAS (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Erin Linden
612-625-2273
linde491@umn.edu
Erin Linden
612-625-2273
linde491@umn.edu
University of Minnesota
Interventions
  • Diagnostic Test: 2-Week Home Monitoring — Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.
  • Diagnostic Test: 6-Week Home Monitoring — HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Discharged after delivery at University of Minnesota Medical Center * Enrolled into the HOPE-BP Program Exclusion Criteria: * Ongoing antihypertensive medication use at 2 weeks (time of randomization) * Have a medical comorbidity that would not be clinically appropriate to randomize * Patients opted out of clinical research
Conditions Asymptomatic Atrial Fibrillation
Phase Not Applicable
Enrollment 499
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Atrial fibrillation is a highly prevalent and incidental arrhythmia, often asymptomatic, and frequently detected incidentally or in association with a stroke. Subclinical atrial fibrillation increases cardioembolic risk, highlighting the need for timely diagnosis. New wireless devices capable of recording heart rhythm, combined with innovative artificial intelligence tools, could be useful in the prediction and detection of this arrhythmia. Objective: to determine the usefulness of home blood pressure and heart rhythm monitoring strategy in the detection of subclinical atrial fibrillation. Methods: observational, cohort, prospective, multicenter study involving 25 researchers from six Latin American countries. Home blood pressure monitoring and single-lead electrocardiogram recording were performed in a population at moderate to high risk of developing atrial fibrillation. A minimum of twenty 30-second electrocardiographic and blood pressure recordings over 7 days using an Omron Complete Hem-7530 T ECG device will be uploaded from a mobile phone app and then sent to a database for analysis. Conclusions: the results of this study can provide a simple and accessible home monitoring system for detecting subclinical atrial fibrillation and for optimizing the predictive capacity of arrhythmia risk scores through deep learning.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Home ECG monitoring — The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download will be available from Omron Connect free of charge on the Google Play Store: https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron\_connect\&hl=es\_419\&pli=1 and on the iOS App Store: https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings will be required daily: the first in the morning before breakfast and taking the prescribed medication, and another in the evening before dinner and taking the afternoon/evening medication. Additional ECG recordings will be required if the patient experiences any symptoms.

Primary Outcomes

  • new atrial fibrillation (one year)
  • The absolute numbers of patients with new atrial fibrillation (one year)
  • The percentage of patients with new atrial fibrillation (one year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-01
Completion: 2025-12-30
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 499 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cardiovascular Research Center Rosario British Sanatorium
Principal Investigators:
  • Daniel L Piskorz, MD (STUDY_CHAIR) - British Sanatorium Cardiovascular Research Center
Contact Information
Study Contact:
Daniel L Piskorz, MD
5493415416828
daniel.l.piskorz@gmail.com
Ricardo López Santi, MD
54 92215081467
lopezsan@live.com.ar
Daniel L Piskorz, MD
54 93415416828
daniel.l.piskorz@gmail.com
British Sanatorium Cardiovascular Research Center
Interventions
  • Device: Home ECG monitoring — The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download will be available from Omron Connect free of charge on the Google Play Store: https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron\_connect\&hl=es\_419\&pli=1 and on the iOS App Store: https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings will be required daily: the first in the morning before breakfast and taking the prescribed medication, and another in the evening before dinner and taking the afternoon/evening medication. Additional ECG recordings will be required if the patient experiences any symptoms.
Study Locations (1 sites)
British Sanatorium Cardiovascular Research Center, Rosario, Santa Fe Province 2000 Argentina
Eligibility Criteria
Inclusion Criteria: * 1\. Hypertensive patients of both sexes over 75 years of age. 2. Hypertensive patients between 65 and 75 years of age are associated with one of the following risk factors: 1. Obesity 2. Type 2 diabetes 3. Obstructive sleep apnea syndrome 4. Electrocardiogram showing left ventricular hypertrophy. 5. Left ventricular hypertrophy on echocardiogram. 6. Left atrial dilation. 7. Coronary artery disease 8. Chronic kidney disease 9. Heart failure with ejection fraction \> 50% 10. Alcohol intake 11. Frequent supraventricular ectopic beats Exclusion Criteria: * 1\. History of any type of atrial fibrillation. 2. Receiving pharmacological treatments with potential impact on heart rhythm. 3. History of potentially malignant ventricular arrhythmias. 4. Uncontrolled hypothyroidism or hyperthyroidism. 5. Significant chronic obstructive pulmonary disease.